Next Article in Journal
Ciona as a Simple Chordate Model for Heart Development and Regeneration
Next Article in Special Issue
The Dorsal Mesenchymal Protrusion and the Pathogenesis of Atrioventricular Septal Defects
Previous Article in Journal
Vascular Development and Regeneration in the Mammalian Heart
Article Menu

Export Article

Open AccessReview
J. Cardiovasc. Dev. Dis. 2016, 3(3), 24; doi:10.3390/jcdd3030024

Stem Cell Therapy and Congenital Heart Disease

1
Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
2
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
3
Transplant Center, Mayo Clinic, Rochester, MN 55905, USA
4
Center for Regenerative Medicine, Mayo Clinic, Rochester, MN 55905, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Andy Wessels
Received: 14 April 2016 / Revised: 7 June 2016 / Accepted: 28 June 2016 / Published: 5 July 2016
View Full-Text   |   Download PDF [236 KB, uploaded 5 July 2016]

Abstract

For more than a decade, stem cell therapy has been the focus of intensive efforts for the treatment of adult heart disease, and now has promise for treating the pediatric population. On the basis of encouraging results in the adult field, the application of stem cell-based strategies in children with congenital heart disease (CHD) opens a new therapy paradigm. To date, the safety and efficacy of stem cell-based products to promote cardiac repair and recovery in dilated cardiomyopathy and structural heart disease in infants have been primarily demonstrated in scattered clinical case reports, and supported by a few relevant pre-clinical models. Recently the TICAP trial has shown the safety and feasibility of intracoronary infusion of autologous cardiosphere-derived cells in children with hypoplastic left heart syndrome. A focus on preemptive cardiac regeneration in the pediatric setting may offer new insights as to the timing of surgery, location of cell-based delivery, and type of cell-based regeneration that could further inform acquired cardiac disease applications. Here, we review the current knowledge on the field of stem cell therapy and tissue engineering in children with CHD, and discuss the gaps and future perspectives on cell-based strategies to treat patients with CHD. View Full-Text
Keywords: congenital heart disease; regenerative medicine; stem cell therapy; heart failure congenital heart disease; regenerative medicine; stem cell therapy; heart failure
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Nelson, T.J.; Cantero Peral, S. Stem Cell Therapy and Congenital Heart Disease. J. Cardiovasc. Dev. Dis. 2016, 3, 24.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Cardiovasc. Dev. Dis. EISSN 2308-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top